Clinical Trial Update: CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab [Phase 2]

View source ↗

Summary

A Phase 2 trial at Johns Hopkins evaluated a combination of CTLA-4 and PD-L1 blockade (tremelimumab and durvalumab) after DEB-TACE in intermediate-stage hepatoc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-08-17